Statistiche di base
| CIK | 1503274 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Quanterix Corporation
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 26, 2026 |
Exhibit 10.1 Quanterix 900 Middlesex Turnpike | Building 1 Billerica, MA 01821 Anthony Catalano Delivered via Email Re: Employment Agreement Dear Anthony: Quanterix Corporation (the "Company") is pleased to offer you the full-time, exempt position of Chief Operations Officer, reporting to Everett Cunningham, Chief Executive Officer. Your start date will be May 14, 2026. This role is required to be |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2026 |
Quanterix Announces Planned Transition of Chief Financial Officer Exhibit 99.1 Quanterix Announces Planned Transition of Chief Financial Officer BILLERICA, Mass.-May 12, 2026- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sr |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-(e)(2)) ☐ Definitive Proxy Statem |
|
| May 6, 2026 |
Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2026 Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness BILLERICA, Mass. – May 6, 2026 - Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating b |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2026 |
q1-26earningspresentatio First Quarter 2026 Earnings Presentation May 6, 2026 Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 6, 2026 |
Exhibit 10.1 DIRECTOR COMPENSATION POLICY Amended and Restated Quanterix Corporation Non-Employee Director Compensation Policy Effective as of January 1, 2025, amended November 20, 2025 I.Overview The Board of Directors (the “Board”) of Quanterix Corporation (the “Company”) has approved this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) to provide an inducement to a |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 6, 2026 |
Employee Non-Competition Agreement Exhibit 10.5 Quanterix 900 Middlesex Turnpike Building 1 Billerica, MA 01821 tel: 617.301.9400 fax: 617.301.9401 www.quanterix.com May 5, 2026 Vandana Sriram Delivered via Email RE: Second Amendment to Employment Agreement Dear Vandana: I am pleased to inform you that the Compensation Committee of the Board of Directors of Quanterix Corporation (the “Company”) has approved a further enhancement of |
|
| May 6, 2026 |
Exhibit 18.1 May 6, 2026 The Board of Directors Quanterix Corporation Billerica, Massachusetts Ladies and Gentlemen: We have been furnished with a copy of the quarterly report on Form 10-Q of Quanterix Corporation and subsidiaries (the Company) for the three months ended March 31, 2026, and have read the Company’s statements contained in Note 2 to the consolidated financial statements included the |
|
| April 24, 2026 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 24, 2026 |
2025 ANNUAL REPORT To Quanterix Stockholders: I’m excited to be sharing my first letter with you as the President & CEO of Quanterix Corporation. |
|
| March 5, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 5, 2026 |
As filed with the Securities and Exchange Commission on March 5, 2026 As filed with the Securities and Exchange Commission on March 5, 2026 Registration No. |
|
| March 2, 2026 |
QUANTERIX CORPORATION INSIDER TRADING POLICY TABLE OF CONTENTS Exhibit 19.1 QUANTERIX CORPORATION INSIDER TRADING POLICY TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 3 II. What is Material Non-Public Information? 3 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading. 5 Transactions by Family Members, Others in Your Household and Entities You Control. 5 Other Companies’ Non-public Information. 1 Person |
|
| March 2, 2026 |
q4-25earningspresentatio 1 Fourth Quarter & Full Year 2025 Earnings Presentation March 2, 2026 2 Legal Information USE OF NON-GAAP FINANCIAL MEASURES To supplement Quanterix's preliminary financial information presented on a GAAP basis, Quanterix has provided certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted cash usage, adjusted gross profit, adjusted gross margin, adjusted total operating expenses, and adjusted loss from operations. |
|
| March 2, 2026 |
Exhibit 10.12 Amended and Restated Quanterix Corporation Non-Employee Director Compensation Policy Effective as of January 1, 2025 I.Overview The Board of Directors (the “Board”) of Quanterix Corporation (the “Company”) has approved this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) to provide an inducement to attract and retain the services of qualified persons to |
|
| March 2, 2026 |
Exhibit 10.17 Manufacturing Agreement Whereas, Columbia Electrical Contractors, Inc. d/b/a Columbia Tech, a Massachusetts corporation with a principal place of business of 27 Otis Street, Westborough, MA 01581 (“Columbia Tech”), provides contract manufacturing services; Whereas, Akoya Biosciences, Inc., a Delaware corporation with a place of business at 68 Elm Street, Hopkinton, MA 01748 (“Custome |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 2, 2026 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025 Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 BILLERICA, Mass. – March 2, 2026 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 2, 2026 |
Exhibit 10.8 Quanterix 900 Middlesex Turnpike Billerica, MA 01821 tel: 617.301.9400 fax: 617.301.9401 www.quanterix.com November 20, 2025 Re: Employment Agreement Dear Bill: This Employment Agreement (the “Agreement”) is entered into between you, William P. Donnelly, and Quanterix Corporation (the “Company”), and is effective as of November 20, 2025 (the “Effective Date”). 1.Role. As of the Effect |
|
| March 2, 2026 |
Exhibit 21.1 SUBSIDIARIES Company Name Jurisdiction of Incorporation Akoya Biosciences, Inc. Delaware Akoya Biosciences UK Ltd. United Kingdom Aushon Biosystems, Inc. Delaware Emission Inc. Delaware Quanterix Bio-tech (Shanghai) Co., Ltd China Quanterix Holdings (Hong Kong) Limited Hong Kong Quanterix Netherlands B.V. The Netherlands Quanterix Security Corporation Massachusetts UmanDiagnostics AB |
|
| January 15, 2026 |
QUANTERIX CORPORATION AMENDED AND RESTATED 2025 INDUCEMENT PLAN Exhibit 99.1 QUANTERIX CORPORATION AMENDED AND RESTATED 2025 INDUCEMENT PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Quanterix Corporation Amended and Restated 2025 Inducement Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Commit |
|
| January 15, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| January 15, 2026 |
As filed with the Securities and Exchange Commission on January 15, 2026 As filed with the Securities and Exchange Commission on January 15, 2026 Registration No. |
|
| January 8, 2026 |
Exhibit 99.1 Press Release Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 BILLERICA, Mass., January 8, 2026 – (BUSINESS WIRE) – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthc |
|
| January 8, 2026 |
Exhibit 10.1 January 8, 2026 Masoud Toloue Dear Masoud: Quanterix Corporation (the “Company”) acknowledges your efforts and contributions to the Company. This separation agreement and release (the “Separation Agreement”) memorializes the terms of your resignation as of January 19, 2026 (the “Resignation Date”). 1.Resignation. You hereby resign from your position as an employee, President, and Chie |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 8, 2026 |
Exhibit 10.2 January 8, 2026 Everett Cunningham Re: Employment Agreement Dear Everett: Quanterix Corporation (the “Company”) is pleased to offer you the full-time position of President and Chief Executive Officer of the Company, reporting to the Company’s Board of Directors (the “Board”). You shall be nominated to be elected to serve as a member of the Board, effective as of your start date hereun |
|
| December 22, 2025 |
Exhibit 99.3 Restricted Stock Unit No. QUANTERIX CORPORATION Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2025 Inducement Plan 1.Name and Address of Participant: 2.Date of Grant of Restricted Stock Unit Award: 3.Maximum Number of Shares underlying Restricted Stock Unit Award: 4.Vesting of Award: This Restricted Stock Unit Award shall vest as follow |
|
| December 22, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| December 22, 2025 |
QUANTERIX CORPORATION 2025 INDUCEMENT PLAN Exhibit 99.1 QUANTERIX CORPORATION 2025 INDUCEMENT PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Quanterix Corporation 2025 Inducement Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term “Administrator |
|
| December 22, 2025 |
Exhibit 99.2 Option No. QUANTERIX CORPORATION Stock Option Grant Notice Stock Option Grant under the Company’s 2025 Inducement Plan 1.Name and Address of Participant: 2.Date of Option Grant: 3.Type of Grant: Non-Qualified Option 4.Maximum Number of Shares for which this Option is exercisable: 5.Exercise (purchase) price per share: 6.Option Expiration Date: 7.Vesting Start Date: 8.Vesting Schedule: |
|
| December 22, 2025 |
As filed with the Securities and Exchange Commission on December 22, 2025 As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 20, 2025 |
Exhibit 99.1 Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director BILLERICA, Mass. – November 20, 2025 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by ac |
|
| November 10, 2025 |
Quanterix Releases Financial Results for the Third Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2025 BILLERICA, Mass. – November 10, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we delivered on our revenue e |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2025 |
q3-25earningsslidesxdraf „ Third Quarter 2025 Earnings N o ve m ber 1 0 , 2 0 2 5 2 USE OF NON-GAAP FINANCIAL MEASURES To supplement Quanterix's preliminary financial information presented on a GAAP basis, Quanterix has provided certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted cash usage, adjusted gross profit, adjusted gross margin, adjusted total operating expenses, and adjusted loss from operations. |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| October 2, 2025 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF QUANTERIX CORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Quanterix Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with the S |
|
| October 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commissio |
|
| October 2, 2025 |
QUANTERIX CORPORATION RESTATED BYLAWS (effective September 29, 2025) ARTICLE I - STOCKHOLDERS Exhibit 3.2 QUANTERIX CORPORATION RESTATED BYLAWS (effective September 29, 2025) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board o |
|
| September 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-(e)(2)) ¨ Definitive Proxy Statem |
|
| September 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 23, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On July 8, 2025 (the “Closing Date”), Quanterix Corporation, a Delaware corporation (the “Company” or “Quanterix”), completed the transactions contemplated by the Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025 (the “Merger Agreement”), by and among the Company, Wellfleet Merger Sub, Inc., a Dela |
|
| September 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 25, 2025 |
2024 ANNUAL REPORT Dear Fellow Quanterix Stockholders, 2024 marked an important step forward for Quanterix. |
|
| August 8, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2025 |
Amendment to Supply and Manufacturing Agreement Exhibit 10.5 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH INFORMATION HAS BEEN OMITTED BECAUSE (i) IT IS NOT MATERIAL, AND (ii) IT WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDMENT TO SUPPLY and MANUFACTURING AGREEMENT This Amendment (the “3rd Amendment”) is made and entered into effective as of January 1, 2025 (the |
|
| August 7, 2025 |
q225earningsslides 1 Roadmap to Cash Flow Breakeven in 2026 Q3 2025 Q4 2025 Q1 2026 $64M of the total $85M Cost reduction already implemented Major Milestones Cost Reduction Implemented (Annualized) ✓ Implement one commercial team ✓ Eliminate duplicate G&A • Complete physical consolidation • Implement one Manufacturing team • Combine Lab Services • Complete all Systems and Financial integration $67M $85M $29M Q2 2025 $64M Cost Reduction Realized (in the quarter) $3M $12M ✓ Pre-close cost actions in commercial and operations $15M $21M 2 2025 2026 ~$120M Cash1 $163M cash1 at close (July ‘25) >$100 million cash1 on hand by the time we turn cash flow positive >$100M Cash flow positive in 2026 1. |
|
| August 7, 2025 |
Quanterix Releases Financial Results for the Second Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2025 BILLERICA, Mass. – August 7, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, hig |
|
| August 7, 2025 |
Exhibit 3.1 QUANTERIX CORPORATION RESTATED BYLAWS (effective August 5, 2025) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Di |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 4, 2025 |
Exhibit 99.1 Quanterix Announces Cooperation Agreement with Kent Lake Capital Company and Kent Lake Capital Agree to Identify New Independent Board Member Company will Seek Shareholder Approval to De-Classify its Board of Directors Board of Directors to Adopt Majority Voting Standard in Uncontested Director Elections BILLERICA, Mass.-(BUSINESS WIRE)-Aug. 4, 2025- Quanterix Corporation (“Quanterix” |
|
| August 4, 2025 |
Exhibit 10.1 Execution Version COOPERATION AGREEMENT This cooperation agreement (this “Agreement”) is made and entered into as of August 4, 2025, by and between Quanterix Corporation, a Delaware corporation (the “Company”), on the one hand, and Kent Lake PR LLC, a Puerto Rico limited liability company and the general partner of Kent Lake Partners LP, a Delaware limited partnership (together, “Kent |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 18, 2025 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 11, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities (1) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee (2) Equity Common Stock, par value $0. |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
Form of Inducement Award Grant Notice and Inducement Award Grant Agreement (RSUs). Exhibit 4.2 Restricted Stock Unit No. QUANTERIX CORPORATION Inducement Award Grant Notice 1. Name and Address of Recipient: (“Recipient”) 2. Date of Grant (“Grant Date”) of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This award of restricted stock units (“Restricted Stock Unit Award”) shall vest in full on the first annivers |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| July 8, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum BILLERICA, Mass. – July 8, 2025 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 16, 2025 |
PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-284932 PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Akoya Biosciences, Inc.: As previously announced, Quanterix Corporation (“Quanterix”), Akoya Biosciences, Inc. (“Akoya”) and Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix (“Merger Sub”), entered into an Amended and Restated Agreeme |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| June 11, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR June 11, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 4, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 3, 2025 No. |
|
| June 4, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated April 27, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The Me |
|
| June 3, 2025 |
Via EDGAR June 3, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington D.C. 20549 Attention: Margaret Sawicki and Lauren Nguyen Re: Quanterix Corporation Post-Effective Amendment No. 1 to Registration Statement on Form S-4 Filed May 21, 2025 File No. 333-284932 Dear Mses. Sawicki and Nguyen: On beh |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Quanterix Corporation (Exact name of registrant as specified in its charter) Delaware 001-38319 (State or other jurisdiction of incorporation) (Commission file number) 900 Middlesex Turnpike, Billerica, MA 01821 (Address of principal executive offices, zip code) Vandana Sriram Chief Financ |
|
| May 30, 2025 |
May 30, 2025 Masoud Toloue President and Chief Executive Officer Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Re: Quanterix Corporation Post-Effective Amendment No. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 20, 2025 No. |
|
| May 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carryforward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| May 21, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.3 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the proxy |
|
| May 21, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated April 27, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, and “Th |
|
| May 14, 2025 |
Exhibit 16.1 May 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated May 9, 2025, of Quanterix Corporation and are in agreement with the statements contained in the first sentence of the first paragraph and the second, third, fourth, fifth, sixth, seventh, eighth and ninth paragraphs under (a) Dismissal of Prev |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 12, 2025 |
Quanterix Releases Financial Results for the First Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2025 BILLERICA, Mass. – May 12, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
Quanterix Releases Financial Results for the First Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2025 BILLERICA, Mass. – May 12, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 29, 2025 |
Exhibit 99.2 Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025 Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this “Consent and Waiver”) is made and entered into as of April 28, 2025, by each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”) and Quanterix Corporation, a Delaware corporation (“Parent”). WHEREAS, Parent, Wellfleet Merger Sub, Inc., a Delaware corporation |
|
| April 29, 2025 |
Exhibit 10.3 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this “Consent and Waiver”) is made and entered into as of April 28, 2025, by each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”) and Quanterix Corporation, a Delaware corporation (“Parent”). WHEREAS, Parent, Wellfleet Merger Sub, Inc., a Delaware corporation |
|
| April 29, 2025 |
Exhibit 99.2 Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025 Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities |
|
| April 29, 2025 |
Exhibit 10.3 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
, 2025, by and among the Registrant, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc. EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 29, 2025 |
EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| April 24, 2025 |
Kent Lake Q&A with Investment Community Exhibit 1 Kent Lake Q&A with Investment Community April 24, 2025 Q. How did sell-side analysts interpret the market’s reaction to the merger announcement? A. On the Q4 2024 earnings call (March 17, 2025), CEO Masoud Toloue was specifically asked about the market’s negative reaction to the merger announcement. He blamed Quanterix’s share price decline on an “NIH-pressured environment.”1 In contrast |
|
| April 22, 2025 |
Exhibit 1 |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2025 |
Exhibit 1 |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 18, 2025 |
Exhibit 1 |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 15, 2025 |
PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-284932 PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Quanterix Corporation and Stockholders of Akoya Biosciences, Inc.: As previously announced, Quanterix Corporation (“Quanterix”), Akoya Biosciences, Inc. (“Akoya”) and Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix (“Merger |
|
| April 11, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR April 11, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 10, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| April 10, 2025 |
As filed with the Securities and Exchange Commission on April 10, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 10, 2025 No. |
|
| April 10, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 April 10, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 3 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed April 10, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with resp |
|
| April 10, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR April 10, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 10, 2025 |
Via EDGAR April 10, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington D.C. 20549 Attention: Laura McKenzie, Margaret Sawicki and Lauren Nguyen Re: Quanterix Corporation Amendment No. 2 to Registration Statement on Form S-4 Filed April 4, 2025 File No. 333-284932 Dear Mses. McKenzie, Sawicki and |
|
| April 9, 2025 |
April 9, 2025 Masoud Toloue, Ph.D. President and Chief Executive Officer Quanterix Corp 900 Middlesex Turnpike Billerica, MA 01821 Re: Quanterix Corp Amendment No. 2 to Registration Statement on Form S-4 Filed April 4, 2025 File No. 333-284932 Dear Masoud Toloue Ph.D.: We have conducted a limited review of your registration statement and have the following comment(s). Please respond to this letter |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 4, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.4 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the joint |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 FORM OF SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or other entit |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and |
|
| April 4, 2025 |
Form of Proxy Card for Special Meeting of Quanterix Corporation. Exhibit 99.3 PLEASE MARK, SIGN, DATE AND RETURN YOUR PROXY CARD PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED. QUANTERIX CORPORATION SPECIAL MEETING OF STOCKHOLDERS , 2025 YOUR VOTE IS IMPORTANT Please take a moment now to vote your shares of Quanterix Corporation common stock for the special meeting of stockholders. YOU CAN VOTE TODAY IN ONE OF THREE WAYS: VOTE VIA INTERNET Have your proxy card |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND AKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Construction 10 ARTICLE II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 April 4, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 2 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed April 4, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with respec |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 4, 2025 No. |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND AKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Construction 10 ARTICLE II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and |
|
| April 4, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 FORM OF SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or other entit |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidenti |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 28, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| March 28, 2025 |
Form of Proxy Card for Special Meeting of Quanterix Corporation. Exhibit 99.3 PLEASE MARK, SIGN, DATE AND RETURN YOUR PROXY CARD PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED. QUANTERIX CORPORATION SPECIAL MEETING OF STOCKHOLDERS , 2025 YOUR VOTE IS IMPORTANT Please take a moment now to vote your shares of Quanterix Corporation common stock for the special meeting of stockholders. YOU CAN VOTE TODAY IN ONE OF THREE WAYS: VOTE VIA INTERNET Have your proxy card |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2025 No. |
|
| March 28, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.4 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the joint |
|
| March 28, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR March 28, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 28, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 March 28, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 1 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed March 28, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with resp |
|
| March 19, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 18, 2025 |
Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| March 17, 2025 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth BILLERICA, Mass. – March 17, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 17, 2025 |
DFAN14A 1 n4845x5-dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use |
|
| March 17, 2025 |
Amended and Restated Non-Employee Director Compensation Policy EXHIBIT 10.12 Amended and Restated Quanterix Corporation Non-Employee Director Compensation Policy Effective as of January 1, 2025 I.Overview The Board of Directors (the “Board”) of Quanterix Corporation (the “Company”) has approved this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) to provide an inducement to attract and retain the services of qualified persons to |
|
| March 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
Quanterix Insider Trading Policy EXHIBIT 19.1 QUANTERIX CORPORATION INSIDER TRADING POLICY TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 3 II. What is Material Non-Public Information? 3 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading. 5 Transactions by Family Members, Others in Your Household and Entities You Control. 5 Other Companies’ Non-public Information. 1 Person |
|
| March 17, 2025 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth BILLERICA, Mass. – March 17, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 11, 2025 |
Exhibit 1 Urges Quanterix Shareholders to Vote AGAINST the Proposed Merger with Akoya Biosciences KENT LAKE PR LLC THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. |
|
| March 3, 2025 |
EXHIBIT 99.1 Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition Comments on Director Nominations Received from Kent Lake BILLERICA, Mass. March 3, 2025 - Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2025 |
EXHIBIT 99.1 Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition Comments on Director Nominations Received from Kent Lake BILLERICA, Mass. March 3, 2025 - Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2025 |
February 22, 2025 Masoud Toloue, Ph.D. President and Chief Executive Officer Quanterix Corp 900 Middlesex Turnpike Billerica, MA 01821 Re: Quanterix Corp Registration Statement on Form S-4 Filed February 14, 2025 File No. 333-284932 Dear Masoud Toloue Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 13, 2025 No. |
|
| February 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carryforward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| February 14, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| February 14, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 February 13, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Initially Filed Registration Statement on Form S-4 of Quanterix Corporation, filed February 13, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with respect to the fairness fro |
|
| February 14, 2025 |
QTRX / Quanterix Corporation / AMERIPRISE FINANCIAL INC - EX-99.3 begin 644 ck0001669811-ex993.pdf M)5!$1BTQ+C8-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5AG:5T#N735%!4#M='1VS2 M@N,:BA%%#**B(,'RJFUFJ>LS=C4:LZF[[.C(3\?@4BZIS*%R 8.EP.TTO M@'FDDTW:>X/6O60>]]A]W,U3TD5K.38OW-E8MECR5QSD8NJ 92&#:NBD4' MD?+)'A\W]]E X!$,(HZ%2X6G(+G(O79'!#'TO%]V MF8PM\#<>K]\32E,BGU-G5L:$N8G>WE$I!3K&'^<0152<$0(BH;U% M&&F%]/20O<)#B&SBUT,..HKIESESB:"G4Q&"#7XFJ[?0:%Y J'6%B&4%B0: MTU4TSR"60^MGU)SPP9%?"H/+ |
|
| February 14, 2025 |
QTRX / Quanterix Corporation / AMERIPRISE FINANCIAL INC - EX-99.1 begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C8-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5AF4@,S0O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#* A(,?D""L1%(,"< "=;S0,+U*$@B#$A87P;)2L.X9E. A!TG Q,CPTR0 M& ,CT<1QM/? 0(, %=S"@L-"F5N9'-T%LP(# @-C$R(#-P# M&4)$S B$\/$8@U H51R$%RI0 D0H0E 21,P5G)ZRRV=SE9C,:*2O$D%>.=R= MG;%^51KDI:DDY\A#4I%'1WKDQ&F.ZFJ::#-FHUZ?I?K93,[.T/+;"!ZSHM%( M#$&PI+LY)D/@7[ADZ7JE=^%9M7)R:] |
|
| February 14, 2025 |
Subsidiaries of Quanterix Corporation. Exhibit 21.1 SUBSIDIARIES Company Name Jurisdiction of Incorporation Aushon Biosystems, Inc. Delaware Quanterix Security Corporation Massachusetts Quanterix Netherlands B.V. The Netherlands UmanDiagnostics AB Sweden Quanterix Holdings (Hong Kong) Limited Hong Kong Quanterix Bio-tech (Shanghai) Co., Ltd China Emission Inc. Delaware Wellfleet Merger Sub, Inc. Delaware |
|
| February 14, 2025 |
QTRX / Quanterix Corporation / AMERIPRISE FINANCIAL INC - EX-99.2 begin 644 ck0001669811-ex992.pdf M)5!$1BTQ+C8-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5AF4@,S0O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#* A(,?D""L1%(,"< "?9V(.'[ R01!B2L+X%DI6%%LP(# @-C$R(##ZO(P?;*4P M;C9)3^4:]^*8&^>XAU-A/%93QSBI-$>%FD523\BHTR.Q?-'39A,M?XS@*K.4^/%'K2FYM6^5,YAK"P"7M9'TGT\52 Z.4DHZL M1 W./-++DD4)PK')WMRHETF#>2XT!/6!<6P$XY1-K;27K-)L<]%&V^=B ]%L MJ53VJ-2?RTJ<9A*;XMKJS,8P64GR?70&G:OM |
|
| February 13, 2025 |
Letter AGAINST the Proposed QTRX-AKYA Merger Exhibit 2 Letter AGAINST the Proposed QTRX-AKYA Merger Dear Fellow Quanterix Shareholders: Kent Lake has been an institutional investor in Quanterix (“QTRX”, “The Company”) since 2022 and has extensive understanding of both QTRX’s transformational clinical Alzheimer’s blood testing opportunity, as well as its highly recurring and double-digit growth research and translational use business. |
|
| February 13, 2025 |
EX-3 4 exh3.htm JOINT FILING AGREEMENT Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Quanterix Corporat |
|
| February 13, 2025 |
Transactions in Shares Effected by Kent Lake Partners LP During the Past Sixty Days EX-1 2 exh1.htm TRANSACTIONS IN THE SHARES Exhibit 1 Transactions in Shares Effected by Kent Lake Partners LP During the Past Sixty Days Nature of Transaction Amount of Securities Purchased/(Sold) Price ($) Date of Purchase/Sale Purchase of Common Stock 6,200 $10.4197 12/13/2024 Purchase of Common Stock 18,265 $10.8185 12/16/2024 Purchase of Common Stock 25,535 $11.1635 12/17/2024 Purchase of Comm |
|
| February 11, 2025 |
feb112025425filingfinal Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 16, 2025 |
SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Exhibit 99.1 SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Name Position Brian McKelligon President, Chief Executive Officer and Director Johnny Elk Chief Financial Officer Jennifer Kamocsay General Counsel Pascal Bamford Chief Clinical Officer Niro Ramachandran Chief Business Officer Robert G. Shepler Director, Chairman of the Board Thomas Raffin Director Thomas P. Schnet |
|
| January 16, 2025 |
jpmakoyarule425filing Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 16, 2025 |
BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX SCHEDULE A BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX The name, present principal occupation or employment and citizenship of each member of the Board of Directors and each executive officer of Quanterix are as set forth below. |
|
| January 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2025 |
EXHIBIT 99.1 Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. – Jan. 14, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker dete |
|
| January 14, 2025 |
EXHIBIT 99.1 Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. – Jan. 14, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker dete |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 99.1 Operator^ Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following the prepared remarks. As a reminder, this conference call is being recorded and the press release and slide presentation regarding the transactions are available at |
|
| January 10, 2025 |
EXHIBIT 10.2 Execution version STOCKHOLDER LOCK-UP AGREEMENT January 9, 2025 Quanterix Corporation 900 Middlesex Turnpike Billerica, MA Attention: Legal Department Email: [email protected] To the addressee set forth above: The undersigned understands that, on the date hereof, Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly |
|
| January 10, 2025 |
EXHIBIT 99.2 Team, Diseases like cancer begin in tissue, spread to blood and often end up in other organs such as lung and liver that ultimately take life. To effectively detect and treat disease, we must measure signals as they follow this pathway. Our vision is to bring clinical and anatomical pathology together to solve this problem. Today we announced our plans to acquire Akoya Biosciences. By |
|
| January 10, 2025 |
EXHIBIT 99.1 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across transla |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.3 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. Together, we’re creating the first pl |
|
| January 10, 2025 |
EXHIBIT 99.1 Operator^ Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following the prepared remarks. As a reminder, this conference call is being recorded and the press release and slide presentation regarding the transactions are available at |
|
| January 10, 2025 |
IMPORTANT ADDITIONAL INFORMATION Exhibit 99.6 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix |
|
| January 10, 2025 |
EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, as of the date he |
|
| January 10, 2025 |
EXHIBIT 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
Why is Quanterix acquiring Akoya? EXHIBIT 99.5 1.Why is Quanterix acquiring Akoya? •The acquisition of Akoya is consistent with our GET strategy and part of the natural evolution of our company. •This is a pivotal step forward in the holistic understanding and treatment of disease. By integrating Akoya’s spatial biology capabilities in tissue with our advanced tools for blood detection, we will create the first integrated solution |
|
| January 10, 2025 |
IMPORTANT ADDITIONAL INFORMATION Exhibit 99.6 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.4 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced our plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. This is a logical next step for Q |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.4 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced our plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. This is a logical next step for Q |
|
| January 10, 2025 |
EXHIBIT 99.2 Team, Diseases like cancer begin in tissue, spread to blood and often end up in other organs such as lung and liver that ultimately take life. To effectively detect and treat disease, we must measure signals as they follow this pathway. Our vision is to bring clinical and anatomical pathology together to solve this problem. Today we announced our plans to acquire Akoya Biosciences. By |
|
| January 10, 2025 |
EXHIBIT 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
qtrx202501108kex992 First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U. |
|
| January 10, 2025 |
Why is Quanterix acquiring Akoya? EXHIBIT 99.5 1.Why is Quanterix acquiring Akoya? •The acquisition of Akoya is consistent with our GET strategy and part of the natural evolution of our company. •This is a pivotal step forward in the holistic understanding and treatment of disease. By integrating Akoya’s spatial biology capabilities in tissue with our advanced tools for blood detection, we will create the first integrated solution |
|
| January 10, 2025 |
EXHIBIT 10.2 Execution version STOCKHOLDER LOCK-UP AGREEMENT January 9, 2025 Quanterix Corporation 900 Middlesex Turnpike Billerica, MA Attention: Legal Department Email: [email protected] To the addressee set forth above: The undersigned understands that, on the date hereof, Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, as of the date he |
|
| January 10, 2025 |
EXHIBIT 99.1 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across transla |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.3 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. Together, we’re creating the first pl |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U. |
|
| January 8, 2025 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Comm |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Com |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| December 17, 2024 |
Exhibit 2.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH INFORMATION HAS BEEN OMITTED BECAUSE (i) IT IS NOT MATERIAL, AND (ii) IT WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED SHARE PURCHASE AGREEMENT BY AND AMONG QUANTERIX CORPORATION, EMISSION INC., THE SHAREHOLDERS OF EMISSION INC. AND THE SHAREHOLDER REPRESENTATIVE Dated as o |
|
| December 17, 2024 |
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION Exhibit 99.1 Quanterix Expands Capabilities with Strategic Acquisition of EMISSION Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. - December 17, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announc |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 22, 2024 |
Quanterix Announces Receipt of Expected Notice from Nasdaq EX-99.1 2 qtrx-20241122xex991.htm EX-99.1 Exhibit 99.1 Quanterix Announces Receipt of Expected Notice from Nasdaq BILLERICA, Mass.—November 22, 2024 — Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for t |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-38319 CUSIP Number: 74766Q101 (Check one): ☐Form 10-K ☐Form 20-F ☐Form 11-K x Form 10-Q ☐Form 10-D ☐Form N-CEN ☐Form N-CSR For Period Ended: September 30, 2024 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition |
|
| November 13, 2024 |
QTRX / Quanterix Corporation / Portolan Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2428231d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. 1)* Quanterix Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 74766Q101 (CUSIP Number) Sept |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024 Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook BILLERICA, Mass. |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| October 3, 2024 |
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors Exhibit 99.1 Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors BILLERICA, Mass. - October 2, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Lieb |
|
| August 21, 2024 |
Jeffrey Elliott Appointed to Quanterix’s Board of Directors Exhibit 99.1 Jeffrey Elliott Appointed to Quanterix’s Board of Directors BILLERICA, Mass. - August 19, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 8, 2024 |
Quanterix Releases Financial Results for the Second Quarter of 2024 Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2024 BILLERICA, Mass. – August 8, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. “Our research business once again delivered strong performance in the second quarte |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| June 27, 2024 |
QTRX / Quanterix Corporation / Portolan Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm2418374d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. )* Quanterix Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 74766Q101 (CUSIP Number) June 17, 2 |
|
| June 7, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Quanterix Corporation (Exact name of registrant as specified in its charter) Delaware 001-38319 (State or other jurisdiction of incorporation) (Commission file number) 900 Middlesex Turnpike, Billerica, MA 01821 (Address of principal executive offices, zip code) Vandana Sriram Chief Financ |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 7, 2024 |
Quanterix Releases Financial Results for the First Quarter of 2024 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2024 BILLERICA, Mass. – May 7, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. “Building on the foundation our team developed last year, Quanterix is entering a new in |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 15, 2024 |
2023 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2024 |
Exhibit 10.2 Vandana Sriram April 9, 2024 Delivered via Email RE: Amendment to Employment Agreement Dear Vandana: I am pleased to inform you that the compensation committee of the Board of Directors of Quanterix Corporation (the “Company”) has approved the enhancement of certain executive-level severance and change in control benefits applicable to you. Changes to your employment agreement, dated |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 12, 2024 |
Exhibit 10.1 Masoud Toloue April 9, 2024 Delivered via Email RE: Amendment to Employment Agreement Dear Masoud: I am pleased to inform you that the compensation committee of the Board of Directors of Quanterix Corporation (the “Company”) has approved a modification to the change in control benefits applicable to you. Changes to your amended and restated employment agreement, dated April 25, 2022 ( |
